New cholesterol drug SHR-1918 enters final testing phase
NCT ID NCT07230730
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether the experimental drug SHR-1918 can safely lower LDL cholesterol and triglycerides in 900 adults with hyperlipidemia who are already on statins. Participants are randomly assigned to receive SHR-1918 or a placebo. The study aims to see if the drug improves key lipid levels over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-1918
- What this could lead to
- If successful, SHR-1918 could offer a new option to help control high cholesterol and triglycerides in people already taking statins.
- What could go wrong
- This is a phase 3 trial, but results may not show a meaningful benefit over placebo. Side effects are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two experimental pills work together safely? a trial seeks answers
- Can a new pill tame high cholesterol? a phase 1 trial puts SAL0167 to the test
- Gut bacteria may tame pancreatitis — probiotic combo put to the test
- Fatty meals may trap vitamin e in the blood, study suggests
- Could vinegar and fasting fix prediabetes cholesterol?
- Could a monthly shot beat biweekly for lowering cholesterol?